ATTACH Platform May Optimize Solid‑Tumor Immunotherapy
Physicians Weekly reports on a preclinical study in the Journal for ImmunoTherapy of Cancer describing ATTACH, a microfluidic platform from MD Anderson researchers that uses tumor cells and controlled shear stress to isolate tumor-reactive T cells by binding avidity. Tested in human and mouse systems, it is not a treatment, not ready for patients, and needs further validation including animal studies.
Why it matters: Relevant to oncology clinicians and referrers following early-stage research into cell therapies such as tumor-infiltrating lymphocyte therapy for solid tumors.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to physiciansweekly.com. October 14, 2026.
